DAPAGLIFLOZIN

Pre-LaunchSM

dapagliflozin

ANDAORALTABLET
Lifecycle
Pre-Launch
Clinical Trials
20

Mechanism of Action

Sodium-glucose cotransporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose and…

Clinical Trials (5)

NCT07450820N/ARecruiting

OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD

Started Feb 2026
14,308 enrolled
Chronic Kidney Disease
NCT07404137Phase 1Recruiting

A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food

Started Feb 2026
26 enrolled
Healthy Participants
NCT06072326Phase 2Not Yet Recruiting

dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation

Started Jan 2026
NCT07222917Phase 2Recruiting

A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.

Started Dec 2025
218 enrolled
Chronic Kidney Disease and Hypertension
NCT07033585Phase 2/3Active Not Recruiting

Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers

Started Jun 2025